Effects of early PCSK9 inhibitor application on inflammation levels and microcirculatory function after PCI in patients with NSTE-ACS

被引：5

作者：

Ji, Jinrui ^{[1
]}

Wei, Xiaoyun ^{[1
]}

Chen, Wenshan ^{[1
]}

Wan, Dongyu ^{[1
]}

Han, Wenjie ^{[1
]}

Liu, Hengliang ^{[1
]}

机构：

[1] Henan Univ Tradit Chinese Med, Sch Clin Med 5, Dept Cardiol, Zhengzhou 450000, Henan, Peoples R China

来源：

AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH | 2023年 / 15卷 / 05期

关键词：

Proprotein convertase subtilisin; kexin; 9; non-ST segment elevation acute coronary syndrome; inflam-mation levels; microcirculatory function; LOW-DENSITY-LIPOPROTEIN; MICROVASCULAR DYSFUNCTION; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; CORONARY; OUTCOMES; MUSCLE; TRIAL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: To investigate inflammation levels and microcirculatory function following the early application of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor after percutaneous coronary intervention (PCI) in pa-tients with non-ST segment elevation acute coronary syndrome (NSTE-ACS). Methods: This is a retrospective study. Between December 2019 and December 2021, 120 patients with NSTE-ACS admitted to the People's Hospital of Henan University of Traditional Chinese Medicine for PCI were randomized via a web-based randomization system into a control group (60 cases) treated with atorvastatin or a PCSK9 inhibitor group (60 cases) treated with atorvas-tatin + evolocumab. After 6 months of treatment, between-group differences were assessed for the following mea-sures: triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), lipoprotein(a) [Lp(a)], high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-& alpha;), interleukin-6 (IL-6), index of microcirculatory resistance (IMR), Thrombosis in Myocardial Infarction myocar-dial perfusion grading (TMPG), major adverse cardiovascular events (MACEs), and adverse reactions. Results: After 6 months of treatment, TG (P=0.037), TC (P<0.001), LDL-C (P<0.001), Lp(a) (P<0.001), hs-CRP (P<0.001), TNF-& alpha; (P<0.001), and IL-6 (P<0.001) levels and IMR values (P<0.001) were significantly lower in the PCSK9 inhibitor group than in the control group. TMPG grade 3 (P=0.04) was noted to occur significantly more frequently in the PCSK9 inhibitor group than in the control group. No significant between-group differences in MACEs (P>0.05) or adverse reactions (P>0.05) were observed. Conclusions: Compared with statins alone, a PCSK9 inhibitor combined with statins improves inflammation levels and microcirculatory function after PCI in patients with NSTE-ACS, and this strategy deserves clinical attention.

引用

页码：3586 / 3596

页数：11

共 31 条

[1] Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study [J].

Allahyari, Ali ;

Jernberg, Tomas ;

Hagstrom, Emil ;

Leosdottir, Margret ;

Lundman, Pia ;

Ueda, Peter .

EUROPEAN HEART JOURNAL, 2020, 41 (40) :3900-3909

[2] Invasive measurement of coronary microvascular resistance in patients with acute myocardial infarction treated by primary PCI [J].

Amier, Raquel P. ;

Teunissen, Paul F. A. ;

Marques, Koen M. ;

Knaapen, Paul ;

van Royen, Niels .

HEART, 2014, 100 (01) :13-20

[3] Morphological stabilization and regression of carotid plaque following therapy with evolocumab in a high-risk patient [J].

Aranzulla, Tiziana Claudia ;

Musumeci, Giuseppe .

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2021, 97 (06) :E835-E841

[4] Reducing Cardiac Injury during ST-Elevation Myocardial Infarction: A Reasoned Approach to a Multitarget Therapeutic Strategy [J].

Bellis, Alessandro ;

Di Gioia, Giuseppe ;

Mauro, Ciro ;

Mancusi, Costantino ;

Barbato, Emanuele ;

Izzo, Raffaele ;

Trimarco, Bruno ;

Morisco, Carmine .

JOURNAL OF CLINICAL MEDICINE, 2021, 10 (13)

[5] Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) [J].

Bonaca, Marc P. ;

Nault, Patrice ;

Giugliano, Robert P. ;

Keech, Anthony C. ;

Pineda, Armando Lira ;

Kanevsky, Estella ;

Kuder, Julia ;

Murphy, Sabina A. ;

Jukema, J. Wouter ;

Lewis, Basil S. ;

Tokgozoglu, Lale ;

Somaratne, Ransi ;

Sever, Peter S. ;

Pedersen, Terje R. ;

Sabatine, Marc S. .

CIRCULATION, 2018, 137 (04) :338-350

[6] Enzymatically Modified Low-Density Lipoprotein Promotes Foam Cell Formation in Smooth Muscle Cells via Macropinocytosis and Enhances Receptor-Mediated Uptake of Oxidized Low-Density Lipoprotein [J].

Chellan, Bijoy ;

Reardon, Catherine A. ;

Getz, Godfrey S. ;

Bowman, Marion A. Hofmann .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (06) :1101-+

[7] Coronary endothelial dysfunction in patients with early coronary artery disease is associated with the increase in intravascular lipid core plaque [J].

Choi, Byoung-Joo ;

Prasad, Abhiram ;

Gulati, Rajiv ;

Best, Patricia J. ;

Lennon, Ryan J. ;

Barsness, Gregory W. ;

Lerman, Lilach O. ;

Lerman, Amir .

EUROPEAN HEART JOURNAL, 2013, 34 (27) :2047-2054

[8]

Collet JP, 2021, REV ESP CARDIOL, V74, DOI [10.1093/eurheartj/ehaa575, 10.1016/j.rec.2021.05.002]

[9] Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases JACC State-of-the-Art Review [J].

Del Buono, Marco Giuseppe ;

Montone, Rocco A. ;

Camilli, Massimiliano ;

Carbone, Salvatore ;

Narula, Jagat ;

Lavie, Carl J. ;

Niccoli, Giampaolo ;

Crea, Filippo .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (13) :1352-1371

[10] PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy [J].

Ding, Zufeng ;

Wang, Xianwei ;

Liu, Shijie ;

Shahanawaz, Jiwani ;

Theus, Sue ;

Fan, Yubo ;

Deng, Xiaoyan ;

Zhou, Sichang ;

Mehta, Jawahar L. .

CARDIOVASCULAR RESEARCH, 2018, 114 (13) :1738-1751

← 1 2 3 4 →